Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Singapore’s Health System Holds Promise To Develop Drug Monitoring Devices

This article was originally published in PharmAsia News

Executive Summary

With Singapore’s biomedical infrastructure and small population, it is an ideal place to test devices that could redefine the way therapies are developed and monitored.

You may also be interested in...



“Adaptive Licensing” Proposals View REMS As Answer To Limited Evidence

Some ideas for new drug approval pathways seem to envision the use of Risk Evaluation and Mitigation Strategies as a means for preventing and monitoring off-label use following initial approval, apparently without regard to the seriousness or extent of a product’s risks. Given the burdens currently created by REMS, any effort to expand and retrofit the programs to a new approval pathway is likely to draw pushback from the health care community.

U.S. FDA Envisions Many Regulatory Coalitions Dealing With Globalization Issues

U.S. FDA could help create several international coalitions to carry out its new globalization plan, which could allow for issue-specific groups focused on individual pharmaceutical sectors

Opportunities Outweigh Challenges For Postmarketing Studies – BMS Exec

SHANGHAI - Both challenges and opportunities exist for conducting post-marketing safety studies for drugs, but the opportunities far outweigh the challenges, Bristol-Myers Squibb VP Medical Safety Amrit Ray said Oct. 30 at Shanghai Institute for Food and Drug Safety's 2008 Drug Safety and Public Policy International Conference

Topics

UsernamePublicRestriction

Register

SC081895

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel